Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$478.65 8.91 (1.90)%

High 483.00 Low 469.20 Volume 503,575 Market Cap 49.96B
08/22/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Aug 14

    Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus

    Read on
  • Aug 03

    Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast

    Read on

EVENTS

  • ASRS 2017
    Aug 14, 2017

  • Regeneron Corporate Presentation August 2017
    Aug 8, 2017

Events & Presentations

NASDAQ REGN

$478.65 8.91 (1.90)%

High 483.00 Low 469.20 Volume 503,575 Market Cap 49.96B
08/22/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information